Search
for

    Glossary Imatinib

    targets specific enzymes to treat certain cancers like CML

    Imatinib, also known as Gleevec, is a targeted cancer therapy drug used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It works by inhibiting specific tyrosine kinases, which are enzymes that promote the growth of cancer cells, thereby slowing or stopping the progression of the disease.

    Research 10 of 206

    1. Hair graying and loss induced by imatinib mesylate The Journal of Dermatology · 2013 · 7 citations
    2. Imatinib-induced classical lichen planopilaris in blaschko-linear distribution leading to cicatricial alopecia Indian Dermatology Online Journal · 2021 · 2 citations
    3. Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib Journal of clinical medicine · 2023
    4. Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects Current drug metabolism · 2009 · 508 citations
    5. The PDGF/PDGFR pathway as a drug target Molecular Aspects of Medicine · 2017 · 182 citations
    6. Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions Advances in wound care · 2016 · 178 citations
    7. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas British Journal of Dermatology · 2003 · 68 citations
    8. Tyrosine kinase inhibition and grey hair The Lancet · 2003 · 59 citations
    9. Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia Journal of the American Academy of Dermatology · 2013 · 25 citations
    10. Skin toxicity of anti‐cancer therapy Journal der Deutschen Dermatologischen Gesellschaft · 2008 · 19 citations
    All research results →

    Community 1

    1. Ways to prevent hair from becoming grey or delaying the greying of hairs? (Have You Heard of Catalase!?) Reddit · 9 May 2025

    Learn

    — no results

    Try a deeper search in learn →